Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022

SELL
$0.69 - $1.21 $128,592 - $225,502
-186,366 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$1.02 - $3.8 $140,445 - $523,229
137,692 Added 282.89%
186,366 $222,000
Q4 2021

Feb 14, 2022

SELL
$3.26 - $4.66 $138,889 - $198,534
-42,604 Reduced 46.67%
48,674 $159,000
Q3 2021

Nov 15, 2021

SELL
$4.08 - $5.66 $118,630 - $164,570
-29,076 Reduced 24.16%
91,278 $408,000
Q2 2021

Aug 16, 2021

SELL
$5.01 - $7.48 $451,005 - $673,357
-90,021 Reduced 42.79%
120,354 $656,000
Q1 2021

May 17, 2021

BUY
$7.19 - $14.95 $512,941 - $1.07 Million
71,341 Added 51.31%
210,375 $1.57 Million
Q4 2020

Feb 16, 2021

SELL
$6.66 - $14.66 $96,396 - $212,188
-14,474 Reduced 9.43%
139,034 $1.51 Million
Q3 2020

Nov 16, 2020

SELL
$8.69 - $14.47 $812,419 - $1.35 Million
-93,489 Reduced 37.85%
153,508 $1.36 Million
Q2 2020

Aug 14, 2020

BUY
$5.21 - $11.03 $1.29 Million - $2.72 Million
246,997 New
246,997 $2.63 Million
Q1 2020

May 15, 2020

SELL
$4.46 - $9.2 $96,782 - $199,639
-21,700 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$4.52 - $10.1 $98,083 - $219,170
21,700 New
21,700 $150,000
Q2 2019

Aug 14, 2019

SELL
$5.5 - $9.75 $101,964 - $180,755
-18,539 Closed
0 $0
Q1 2019

May 15, 2019

SELL
$5.51 - $9.59 $160,985 - $280,191
-29,217 Reduced 61.18%
18,539 $169,000
Q4 2018

Feb 14, 2019

SELL
$5.55 - $11.34 $51,753 - $105,745
-9,325 Reduced 16.34%
47,756 $266,000
Q3 2018

Nov 14, 2018

BUY
$9.74 - $12.92 $555,968 - $737,486
57,081 New
57,081 $680,000
Q2 2018

Aug 14, 2018

BUY
$10.16 - $13.65 $1.19 Million - $1.6 Million
117,122 New
117,122 $1.2 Million
Q1 2018

May 15, 2018

SELL
$9.47 - $12.98 $200,735 - $275,137
-21,197 Closed
0 $0
Q4 2017

Feb 14, 2018

BUY
$8.45 - $17.48 $79,759 - $164,993
9,439 Added 80.28%
21,197 $206,000
Q3 2017

Nov 14, 2017

BUY
$13.52 - $23.75 $158,968 - $279,252
11,758
11,758 $173,000

About Syros Pharmaceuticals, Inc.


  • Ticker SYRS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 20,236,200
  • Market Cap $43.1M
  • Description
  • Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically def...
More about SYRS
Track This Portfolio

Track Two Sigma Investments, LP Portfolio

Follow Two Sigma Investments, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Investments, LP with notifications on news.